- Home
- RIGL vs WALD Comparison
RIGL vs WALD Comparison
Compare RIGL & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- WALD
- Stock Information
- Founded
- RIGL 1996
- WALD 1988
- Country
- RIGL United States
- WALD United States
- Employees
- RIGL N/A
- WALD N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- WALD Package Goods/Cosmetics
- Sector
- RIGL Health Care
- WALD Consumer Discretionary
- Exchange
- RIGL Nasdaq
- WALD Nasdaq
- Market Cap
- RIGL 335.5M
- WALD 291.5M
- IPO Year
- RIGL 2000
- WALD 2021
- Fundamental
- Price
- RIGL $18.98
- WALD $2.50
- Analyst Decision
- RIGL Buy
- WALD Strong Buy
- Analyst Count
- RIGL 5
- WALD 5
- Target Price
- RIGL $36.40
- WALD $5.16
- AVG Volume (30 Days)
- RIGL 206.5K
- WALD 178.4K
- Earning Date
- RIGL 08-05-2025
- WALD 08-26-2025
- Dividend Yield
- RIGL N/A
- WALD N/A
- EPS Growth
- RIGL N/A
- WALD N/A
- EPS
- RIGL 2.08
- WALD N/A
- Revenue
- RIGL $203,077,000.00
- WALD $273,868,000.00
- Revenue This Year
- RIGL $14.41
- WALD $14.78
- Revenue Next Year
- RIGL $15.97
- WALD $15.84
- P/E Ratio
- RIGL $9.41
- WALD N/A
- Revenue Growth
- RIGL 70.16
- WALD 25.55
- 52 Week Low
- RIGL $8.10
- WALD $1.98
- 52 Week High
- RIGL $29.82
- WALD $4.74
- Technical
- Relative Strength Index (RSI)
- RIGL 45.79
- WALD 49.45
- Support Level
- RIGL $18.24
- WALD $2.51
- Resistance Level
- RIGL $19.38
- WALD $2.72
- Average True Range (ATR)
- RIGL 0.77
- WALD 0.19
- MACD
- RIGL -0.04
- WALD 0.01
- Stochastic Oscillator
- RIGL 43.64
- WALD 46.88
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.